Bacterial, Viral & Fungal Infections • ICD-10-CM B00.50
Herpesviral ocular disease
Audited by the DotMD AI Specialist Council
•
FDA DailyMed SPL: 2026-11-02 • ICD-10-CM B00.50 • 4 Linked .gov / PubMed Citations
•
Governance: Dr. Priya Nair, MD, FAAD (NPI #1295730425)
Methodology & AI Transparency ⓘ
Data on this page is deterministically ingested from official U.S. federal datasets (NIH RxNorm, MedlinePlus, FDA DailyMed SPL, openFDA FAERS, NCBI PubMed, and CMS Medicaid NADAC / Medicare Part B) and translated into plain English by DotMD's 5 specialized AI research agents under NPI-verified clinical governance.
At a Glance • Plain-English Clinical Summary
Herpesviral ocular disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code B00.50 in Infections & Antivirals, Herpesviral ocular disease requires rapid antigen/NAAT PCR in Herpesviral ocular disease (B00.50: diagnostics) so specialists can calibrate treatment intensity against Complete Blood Count in Herpesviral ocular disease (B00.50: (WBC & Differential)) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry B00.50: Herpesviral ocular disease is managed within Infections & Antivirals.
- 3 Typical cash cost range: Primary evaluation for Herpesviral ocular disease incorporates rapid antigen/NAAT PCR in Herpesviral ocular disease (B00.50: diagnostics) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Herpesviral ocular disease: maintaining Complete Blood Count in Herpesviral ocular disease (B00.50: (WBC & Differential)) within WBC 4.0 – 10.0 x10^3/uL (B00.50).
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data
3 of 3 Free Questions RemainingAsk our AI Specialists anything about Herpesviral ocular disease
What Is Herpesviral ocular disease?
Cataloged under federal diagnostic code B00.50 in Infections & Antivirals, Herpesviral ocular disease requires rapid antigen/NAAT PCR in Herpesviral ocular disease (B00.50: diagnostics) so specialists can calibrate treatment intensity against Complete Blood Count in Herpesviral ocular disease (B00.50: (WBC & Differential)) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Herpesviral ocular disease (code B00.50) is tissue neutrophil/lymphocyte recruitment [Herpesviral ocular disease B00.50], which Bacterial, Viral & Fungal Infections clinicians address while surveilling Complete Blood Count in Herpesviral ocular disease (B00.50: (WBC & Differential)) (WBC 4.0 – 10.0 x10^3/uL (B00.50)).
Common Symptoms & Clinical Signs
- • Presentation of Herpesviral ocular disease (B00.50): sore throat, productive in Herpesviral ocular disease (B00.50: cough, sinus/ear pain,)
- • Secondary Herpesviral ocular disease clinical sign: painful vesicular rash in Herpesviral ocular disease (B00.50: in a dermatomal)
- • Symptom flares in Herpesviral ocular disease correlating with Complete Blood Count in Herpesviral ocular disease (B00.50: (WBC & Differential)) deviation outside WBC 4.0 – 10.0 x10^3/uL (B00.50)
- • Functional infections & antivirals impact requiring rapid antigen/NAAT PCR in Herpesviral ocular disease (B00.50: diagnostics) evaluation (B00.50)
Herpesviral ocular disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | B00.50 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Bacterial, Viral & Fungal Infections | NLM Clinical Tables |
| Diagnostic / Lab Marker: Complete Blood Count in Herpesviral ocular disease (B00.50: (WBC & Differential)) | WBC 4.0 – 10.0 x10^3/uL (B00.50) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: C-Reactive Protein / in Herpesviral ocular disease (B00.50: Procalcitonin) | Resolution to baseline (B00.50) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Targeted PCR / in Herpesviral ocular disease (B00.50: Culture & Sensitivity) | Pathogen clearance / negative test (B00.50) | Clinical Reference Target Range |
Marcus Sterling (AI Healthcare Price Auditor) & Dr. Vance
Check Drug Interactions →
FDA-Monographed Medications & Public Cash Price Reference for Herpesviral ocular disease
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Methazolamide Neptazane • RxCUI 197939 | Eye Health Agent | 90% | $0.6275 | $ 17.08 /mo |
| Tobramycin / Dexamethasone Tobradex St, TobraDex • RxCUI 849115 | Aminoglycoside Antibacterial | 91% | $46.6196 | $ 11.38 /mo |
| Neomycin Sulfate, Polymyxin B Sulfate and Dexamethasone Suspension/ Drops Neomycin Polymyxin B Sulfates and Dexamethasone • RxCUI 309680 | Corticosteroid | 83% | $5.3182 | $ 185.00 /mo |
| Povidone-Iodine Betadine, Bd E-Z Scrub • RxCUI 312570 | Antiseptic | 85% | $0.0191 | $ 9.27 /mo |
| Ketorolac Tromethamine Acuvail, Toronova Ii Suik • RxCUI 860107 | Cyclooxygenase Inhibitor | 83% | $12.7675 | $ 6.72 /mo |
| Polymyxin B Sulfate and Trimethoprim Sulfate Polymyxin B Sulfate and Trimethoprim Sulfate Generic • RxCUI 244967 | Dihydrofolate Reductase Inhibitor Antibacterial | 74% | $0.4507 | $ 26.75 /mo |
Dr. Lin (AI PubMed Clinical Trial Lead)
Browse All PubMed Translations →
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Herpesviral ocular disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Iron serum levels and iron homeostasis parameters in patients with nosocomial Clinicaltrials.gov registration: NCT03032380. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology • 2022-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35025025 ↗ |
| Can This Approach Help? Inside the Latest Research on Changes to inflammatory markers during 5 years of viral suppression and during Viral suppression was associated with reductions in most inflammatory markers in PWH, with no significant differences among the three ART regimens during the 144-week randomized period. Frontiers in immunology • 2024-01-15 • Phase III Randomized Trial | N = 123 | 82/100 | PMID 39600696 ↗ |
Zero-PHI Patient Support & Cohort Discussions
Herpesviral ocular disease Patient Community & “People Like Me” Threads
“People Like Me” Cohort Filter (Zero-PHI)
Filter Herpesviral ocular disease community threads and patient logs by age, biological sex, dosage, and treatment duration.
No threads match this cohort filter yet. Click + Start Anonymous Discussion to ask the community about Herpesviral ocular disease.